NLSP — NLS Pharmaceutics AG Income Statement
0.000.00%
Last trade - 00:00- $2.97m
- $4.13m
Annual income statement for NLS Pharmaceutics AG, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 4.56 | 2.3 | 11.9 | 16.4 | 11.8 |
| Operating Profit | -4.56 | -2.3 | -11.9 | -16.4 | -11.8 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -5.45 | -2.86 | -11.9 | -16.5 | -12.2 |
| Net Income After Taxes | -5.45 | -2.86 | -11.9 | -16.5 | -12.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -5.45 | -2.86 | -11.9 | -16.5 | -12.2 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -5.45 | -2.86 | -11.9 | -16.5 | -12.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -17.3 | -9.72 | -40.1 | -31.6 | -12.8 |
| Dividends per Share |